Immunotherapy

Ethnic minorities and people with cancer, particularly those receiving chemotherapy or immunotherapy, demonstrated increased risk for COVID-19, according to results of a study based on self-reported data collected through a smartphone app.

A gamma-delta T-cell therapy failed to significantly prolong PFS for patients with treatment-refractory non-small cell lung cancer, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.

Immunotherapy did not appear to worsen complications among patients with cancer and COVID-19, according to results of a study presented at American Association for Cancer Research Virtual Meeting: COVID-19 and Cancer.

A clinical trial is underway to assess the safety of a novel immunotherapy combination for the treatment of mild to moderate COVID-19 infection among patients with cancer.

The Society for Immunotherapy of Cancer announced the results of its 2020 election, conducted this spring.

Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy.

The use of genomic testing to identify actionable mutations and match patients to targeted therapies has had a dramatic impact on cancer treatment.

A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Choosing the best treatment for a patient with renal cell carcinoma involves a thorough assessment of the potential advantages and drawbacks of each targeted and immune therapy option based on the patient’s risk level and adjustment based on response to frontline treatment.

The treatment landscape for relapsed and refractory small cell lung cancer is an area ripe for investigation.